These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 37330413)

  • 21. The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis.
    Ben-David R; Lidagoster S; Geduldig J; Kolanukuduru KP; Elkun Y; Tillu N; Cumarasamy S; Rich JM; Almoflihi M; Attalla K; Mehrazin R; Wiklund P; Sfakianos JP
    Urol Oncol; 2025 Jan; 43(1):66.e9-66.e17. PubMed ID: 39277526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.
    Ofner H; Laukhtina E; Hassler MR; Shariat SF
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer.
    Grobet-Jeandin E; Lenfant L; Mir C; Giannarini G; Alcaraz A; Albersen M; Breda A; Briganti A; Rouprêt M; Seisen T;
    Eur Urol Oncol; 2023 Jun; 6(3):251-262. PubMed ID: 36906510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
    Huelster HL; Gould B; Schiftan EA; Camperlengo L; Davaro F; Rose KM; Soupir AC; Jia S; Zheng T; Sexton WJ; Pow-Sang J; Spiess PE; Daniel Grass G; Wang L; Wang X; Vosoughi A; Necchi A; Meeks JJ; Faltas BM; Du P; Li R
    Eur Urol; 2024 Mar; 85(3):283-292. PubMed ID: 37802683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Lindskrog SV; Birkenkamp-Demtröder K; Nordentoft I; Laliotis G; Lamy P; Christensen E; Renner D; Andreasen TG; Lange N; Sharma S; ElNaggar AC; Liu MC; Sethi H; Aleshin A; Agerbæk M; Jensen JB; Dyrskjøt L
    Clin Cancer Res; 2023 Dec; 29(23):4797-4807. PubMed ID: 37782315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
    Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
    Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.
    Sargos P; Baumann BC; Eapen L; Christodouleas J; Bahl A; Murthy V; Efstathiou J; Fonteyne V; Ballas L; Zaghloul M; Roubaud G; Orré M; Larré S
    Cancer Treat Rev; 2018 Nov; 70():88-97. PubMed ID: 30125800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
    Singh A; Osbourne AS; Koshkin VS
    Curr Treat Options Oncol; 2023 Sep; 24(9):1213-1230. PubMed ID: 37428331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
    J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Chen J; Zhang H; Sun G; Zhang X; Zhao J; Liu J; Shen P; Shi M; Zeng H
    Int J Surg; 2018 Apr; 52():214-220. PubMed ID: 29496649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.
    Omura M; Kikuchi E; Shigeta K; Ogihara K; Hakozaki K; Hara S; Shirotake S; Ide H; Yoshimine S; Ohigashi T; Mizuno R; Oya M
    Jpn J Clin Oncol; 2022 Apr; 52(4):388-396. PubMed ID: 35106598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
    Beije N; de Kruijff IE; de Jong JJ; Klaver SO; de Vries P; Jacobs RAL; Somford DM; Te Slaa E; van der Heijden AG; Alfred Witjes J; Fossion LMCL; Boevé ER; van der Hoeven J; van Melick HHE; Wijburg CJ; Bickerstaffe H; Martens JWM; de Wit R; Kraan J; Sleijfer S; Boormans JL
    ESMO Open; 2022 Apr; 7(2):100416. PubMed ID: 35248823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.